Claudio D. Schteingart

2.2k total citations
47 papers, 1.7k citations indexed

About

Claudio D. Schteingart is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claudio D. Schteingart has authored 47 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claudio D. Schteingart's work include Drug Transport and Resistance Mechanisms (18 papers), Neuropeptides and Animal Physiology (6 papers) and Neuroendocrine regulation and behavior (6 papers). Claudio D. Schteingart is often cited by papers focused on Drug Transport and Resistance Mechanisms (18 papers), Neuropeptides and Animal Physiology (6 papers) and Neuroendocrine regulation and behavior (6 papers). Claudio D. Schteingart collaborates with scholars based in United States, Switzerland and Argentina. Claudio D. Schteingart's co-authors include Alan F. Hofmann, Alan F. Hofmann, Peter J. Meier, Bruno Hagenbuch, Bruno Stieger, Gerd A. Kullak‐Ublick, Allan W. Wolkoff, Pierre Rivière, Lee R. Hagey and Joseph H. Steinbach and has published in prestigious journals such as Gastroenterology, Hepatology and The Journal of Physical Chemistry B.

In The Last Decade

Claudio D. Schteingart

47 papers receiving 1.7k citations

Peers

Countries citing papers authored by Claudio D. Schteingart

Since Specialization

Citations

This map shows the geographic impact of Claudio D. Schteingart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio D. Schteingart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio D. Schteingart more than expected).

Fields of papers citing papers by Claudio D. Schteingart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudio D. Schteingart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio D. Schteingart. The network helps show where Claudio D. Schteingart may publish in the future.

Co-authorship network of co-authors of Claudio D. Schteingart

This figure shows the co-authorship network connecting the top 25 collaborators of Claudio D. Schteingart. A scholar is included among the top collaborators of Claudio D. Schteingart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudio D. Schteingart. Claudio D. Schteingart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders 2023 ·mAbs ·(unknown), Gregory D. Bowden, Harrison J. Stratton, Kazimierz Wiśniewski, Claudio D. Schteingart, Juan C. Almagro, Philippe Valadon, (unknown), Scott Glaser, Grace Lee, (unknown), Edita Navratilova, Frank Porreca, Pierre Rivière	8
2	Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms 2021 ·The Journal of Clinical Endocrinology & Metabolism ·Elizabeth A. McCarthy, (unknown), (unknown), Silvia León, (unknown), Eugene Cheung, Claudio D. Schteingart, Pierre Rivière, Susan D. Reed, Robert A. Steiner, Víctor M. Navarro	26
3	Discovery of Potent, Selective, and Short-Acting Peptidic V₂ Receptor Agonists 2019 ·Journal of Medicinal Chemistry ·Kazimierz Wiśniewski, (unknown), John E. Kraus, (unknown), Karthik Srinivasan, (unknown), Glenn Croston, (unknown), Halina Wiśniewska, (unknown), Régent Laporte, Pierre Rivière, (unknown), Diane M. Hargrove, Claudio D. Schteingart	7
4	The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis* 2014 ·Critical Care Medicine ·Marc O. Maybauer, Dirk M. Maybauer, Perenlei Enkhbaatar, Régent Laporte, Halina Wiśniewska, Lillian D. Traber, Chii‐Dean Lin, Juanjuan Fan, Hal K. Hawkins, Robert A. Cox, Kazimierz Wiśniewski, Claudio D. Schteingart, Donald W. Landry, Pierre Rivière, Daniel L. Traber	51
5	Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Régent Laporte, (unknown), (unknown), Halina Wiśniewska, (unknown), (unknown), (unknown), Sudarkodi Alagarsamy, (unknown), John Dykert, (unknown), Kazimierz Wiśniewski, Robert Galyean, Glenn Croston, Claudio D. Schteingart, Pierre Rivière	29
6	Synthesis and in vitro Pharmacological Profile of Potent and Selective Peptidic V1a Receptor Agonists. 2009 ·Advances in experimental medicine and biology ·Kazimierz Wiśniewski, Robert Galyean, (unknown), Sudar Alagarsamy, Glenn Croston, Régent Laporte, Claudio D. Schteingart, Pierre Rivière	8
7	FE200041 (d-Phe-d-Phe-d-Nle-d-Arg-NH2): A Peripheral Efficacious κ Opioid Agonist with Unprecedented Selectivity 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Todd W. Vanderah, Claudio D. Schteingart, Jerzy Trojnar, (unknown), Josephine Lai, Pierre Rivière	55
8	Stimulation of the Gonadotropic Axis by the Neuropeptide Y Receptor Y1 Antagonist/ Y4 Agonist 1229U91 in the Male Rat 2000 ·Neuroendocrinology ·Paula Raposinho, Pierre Broqua, (unknown), Karen Akinsanya, Robert Galyean, Claudio D. Schteingart, Jean‐Louis Junien, Michel L. Aubert	30
9	Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats 1999 ·Gastroenterology ·Ulrich Bolder, (unknown), Lee R. Hagey, Claudio D. Schteingart, Huong‐Thu Ton‐Nu, Carolina Cerré, Ronald P.J. Oude Elferink, Alan F. Hofmann	62
10	Transport of fluorescent bile acids by the isolated perfused rat liver: Kinetics, sequestration, and mobilization 1998 ·Hepatology ·F. Holzinger, Claudio D. Schteingart, Huong‐Thu Ton‐Nu, Carolina Cerré, Joseph H. Steinbach, Hong‐Zen Yeh, Alan F. Hofmann	27
11	Successful Topical Dissolution of Cholesterol Gallbladder Stones Using Ethyl Propionate 1997 ·Digestive Diseases and Sciences ·Alan F. Hofmann, A. Amelsberg, (unknown), Claudio D. Schteingart, Kip D. Lyche, (unknown), Eric vanSonnenberg, H B D'Agostino	3
12	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver 1995 ·Gastroenterology ·Gerd A. Kullak‐Ublick, Bruno Hagenbuch, Bruno Stieger, Claudio D. Schteingart, Alan F. Hofmann, Allan W. Wolkoff, Peter J. Meier	333
13	Increased blood levels of methyl tert-butyl ether but not of ethyl propionate during instillation with contact gallstone dissolution agents in the pig 1993 ·Hepatology ·(unknown), Claudio D. Schteingart, D. Pappert, (unknown), Rita Streich, (unknown)	14
14	Effect of replacement therapy with cholylsarcosine on fat malabsorption associated with severe bile acid malabsorption 1992 ·Digestive Diseases and Sciences ·(unknown), Jan Lillienau, Young Soo Kim, Claudio D. Schteingart, R. G. Danzinger, (unknown), Alan F. Hofmann	12
15	Conjugated bile acid uptake by Xenopus laevis oocytes induced by microinjection with ileal poly A+ mRNA 1992 ·Biochemical and Biophysical Research Communications ·Steven Sorscher, Jan Lillienau, Judy L. Meinkoth, Joseph H. Steinbach, Claudio D. Schteingart, James R. Feramisco, Alan F. Hofmann	20
16	Acute Effects of Topical Methyl Tert–Butyl Ether or Ethyl Propionate on Gallbladder Histology in Animals: A Comparison of Two Solvents for Contact Dissolution of Cholesterol Gallstones 1992 ·Hepatology ·(unknown), (unknown), Ronald L. Hamilton, Diane L. Crombie, Claudio D. Schteingart, (unknown), H B D'Agostino, Jan Lillienau, Alan F. Hofmann	11
17	Biological and Medical Aspects of Active Heal Transport of Bile Acids 1991 ·Annals of Medicine ·Alan F. Hofmann, Claudio D. Schteingart, Jan Lillienau	23
18	Active absorption of conjugated bile acids in vivo 1991 ·Gastroenterology ·Joseph H. Steinbach, Huong‐Thu Ton‐Nu, Jan Lillienau, Samuel N. Marcus, Claudio D. Schteingart, (unknown), Alan F. Hofmann, Yun Xia, (unknown), Adrian Schmassmann	50
19	Concentrative biliary secretion of ceftriaxone 1990 ·Gastroenterology ·Yun Xia, Karel J. Lambert, Claudio D. Schteingart, Jingjing Gu, Alan F. Hofmann	48
20	Prevention of Ursodeoxycholate Hepatotoxicity in the Rabbit by Conjugation With N –Methyl Amino Acids 1990 ·Hepatology ·Adrian Schmassmann, Alan F. Hofmann, (unknown), (unknown), Claudio D. Schteingart, Carlo Clerici, Steven S. Rossi, Marcus A. Rothschild, Bertram I. Cohen, Richard J. Stenger, Erwin H. Mosbach	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact